Study Shows Abraxane® Extends Survival For Patients With Advanced Pancreatic Cancer

 Study Shows Abraxane® Extends Survival For Patients With Advanced Pancreatic
                                    Cancer

PR Newswire

MANHATTAN BEACH, Calif., Nov. 9, 2012

MANHATTAN BEACH, Calif., Nov. 9, 2012 /PRNewswire/ -- The Pancreatic Cancer
Action Network is pleased to announce Abraxane® extends survival for patients
with advanced pancreatic cancer. According to Celgene Corporation, Abraxane in
combination with gemcitabine when given to advanced pancreatic cancer patients
who had not received previous treatment demonstrated a statistically
significant improvement in overall survival compared to patients receiving
gemcitabine alone.

(Logo: http://photos.prnewswire.com/prnh/20111004/LA79914LOGO)

The phase III study included 861 metastatic pancreatic cancer patients from
around the world. Full results from the clinical trial will be presented at
the American Society of Clinical Oncology's 2013 Gastrointestinal Cancers
Symposium being held in January.

"Historically, few effective treatment options for pancreatic cancer have
existed. We are thrilled to have a new treatment option for patients with
advanced pancreatic cancer. We look forward to learning more about the
increase in survival when the full results from the study are released in
January," stated Julie Fleshman, president and CEO of the Pancreatic Cancer
Action Network. "Clinical trials represent hope for patients with pancreatic
cancer and we are so appreciative of the patients who participated in this
study. It is the only way to make progress towards better treatments."

Abraxane was previously approved for breast cancer in 2005 and last month was
approved for a type of lung cancer. It is a form of the chemotherapy drug
paclitaxel that is modified by the addition of a human protein called albumin.
The company plans to submit the drug to the FDA for approval in pancreatic
cancer.

The Pancreatic Cancer Action Network encourages all patients to consider
clinical trials when exploring treatment options. Our organization has a
comprehensive up-to-date database of all approved pancreatic cancer-specific
clinical trials taking place nationwide and can do a customized eligibility
search for patients through our Patient and Liaison Services program.

For more information about the Pancreatic Cancer Action Network and clinical
trials visit www.pancan.org. 

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is the national organization creating
hope in a comprehensive way through research, patient support, community
outreach and advocacy for a cure. The organization is leading the way to
increase the survival rate for people diagnosed with this devastating disease
through a bold initiative — The Vision of Progress: Double the Pancreatic
Cancer Survival Rate by 2020. Together, we can know, fight and end pancreatic
cancer by intensifying our efforts to heighten awareness, raise funds for
comprehensive private research, and advocate for dedicated federal research to
advance early diagnostics, better treatments and increase chances of survival.

SOURCE Pancreatic Cancer Action Network

Website: http://www.pancan.org
Contact: Jennifer Reeves, Pancreatic Cancer Action Network, +1-310-706-3362,
jreeves@pancan.org